Induction of Heme Oxygenase-1 by Na+-H+ Exchanger 1 Protein Plays a Crucial Role in Imatinib-resistant Chronic Myeloid Leukemia Cells

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2015 Mar 25

PMID 25802333

Citations 16

Authors

Dan Ma

Qin Fang

Ping Wang

Rui Gao

Weibing Wu

Tangsheng Lu

Lu Cao

Xiuying Hu

Jishi Wang

Affiliations

Soon will be listed here.

Abstract

Resistance toward imatinib (IM) and other BCR/ABL tyrosine kinase inhibitors remains troublesome in the treatment of advanced stage chronic myeloid leukemia (CML). The aim of this study was to estimate the reversal effects of down-regulation of Na(+)/H(+) exchanger 1 (NHE1) on the chemoresistance of BCR-ABL-positive leukemia patients' cells and cell lines. After treatment with the specific NHE1 inhibitor cariporide to decrease intracellular pH (pHi), the heme oxygenase-1 (HO-1) levels of the K562R cell line and cells from IM-insensitive CML patients decreased. HO-1, as a Bcr/Abl-dependent survival molecule in CML cells, is important for the resistance to tyrosine kinase inhibitors in patients with newly diagnosed CML or IM-resistant CML. Silencing PKC-β and Nrf-2 or treatment with inhibitors of p38 pathways obviously blocked NHE1-induced HO-1 expression. Furthermore, treatment with HO-1 or p38 inhibitor plus IM increased the apoptosis of the K562R cell line and IM-insensitive CML patients' cells. Inhibiting HO-1 enhanced the activation of caspase-3 and poly(ADP-ribose) polymerase-1. Hence, the results support the anti-apoptotic role of HO-1 induced by NHE1 in the K562R cell line and IM-insensitive CML patients and provide a mechanism by which inducing HO-1 expression via the PKC-β/p38-MAPK pathway may promote tumor resistance to oxidative stress.

Citing Articles

The Growth Inhibitory Effect of Resveratrol and Gallic Acid on Prostate Cancer Cell Lines through the Alteration of Oxidative Stress Balance: The Interplay between , and Genes.

Moghadam D, Zarei R, Rostami A, Samare-Najaf M, Ghojoghi R, Savardashtaki A Anticancer Agents Med Chem. 2024; 24(16):1220-1232.

PMID: 38984567 DOI: 10.2174/0118715206317999240708062744.

Intracellular Acidification in a Rat C6 Glioma Model following Cariporide Injection Investigated by CEST-MRI.

Mozaffari M, Nystrom N, Li A, Bellyou M, Scholl T, Bartha R Metabolites. 2023; 13(7).

PMID: 37512530 PMC: 10386045. DOI: 10.3390/metabo13070823.

The prognostic and therapeutic potential of HO-1 in leukemia and MDS.

Sadeghi M, Fathi M, Gholizadeh Navashenaq J, Mohammadi H, Yousefi M, Hojjat-Farsangi M Cell Commun Signal. 2023; 21(1):57.

PMID: 36915102 PMC: 10009952. DOI: 10.1186/s12964-023-01074-8.

Extracellular Vesicles and Cell Pathways Involved in Cancer Chemoresistance.

Console L, Scalise M Life (Basel). 2022; 12(5).

PMID: 35629286 PMC: 9143651. DOI: 10.3390/life12050618.

Identification of Novel Anthracycline Resistance Genes and Their Inhibitors.

Kadioglu O, Elbadawi M, Fleischer E, Efferth T Pharmaceuticals (Basel). 2021; 14(10).

PMID: 34681275 PMC: 8540045. DOI: 10.3390/ph14101051.

References

Savona M, Saglio G . Identifying the time to change BCR-ABL inhibitor therapy in patients with chronic myeloid leukemia. Acta Haematol. 2013; 130(4):268-78. DOI: 10.1159/000353163. View

Kim D, Goh H, Kim S, Choi S, Park S, Jang E . Comprehensive therapeutic outcomes of frontline imatinib mesylate in newly diagnosed chronic phase chronic myeloid leukemia patients in Korea: feasibility assessment of current ELN recommendation. Int J Hematol. 2012; 96(1):47-57. DOI: 10.1007/s12185-012-1093-y. View

Yun S, Jung K, Kim S, Fang Z, Son M, Yan H . HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia. Cancer Lett. 2014; 348(1-2):50-60. DOI: 10.1016/j.canlet.2014.03.012. View

Elias M, Baba A, Azlan H, Rosline H, Ai Sim G, Padmini M . BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome. Leuk Res. 2014; 38(4):454-9. DOI: 10.1016/j.leukres.2013.12.025. View

Xenaki D, Pierce A, Underhill-Day N, Whetton A, Jane Owen-Lynch P . Bcr-Abl-mediated molecular mechanism for apoptotic suppression in multipotent haemopoietic cells: a role for PKCbetaII. Cell Signal. 2003; 16(2):145-56. DOI: 10.1016/s0898-6568(03)00101-3. View

Hwang Y, Jeong H . The coffee diterpene kahweol induces heme oxygenase-1 via the PI3K and p38/Nrf2 pathway to protect human dopaminergic neurons from 6-hydroxydopamine-derived oxidative stress. FEBS Lett. 2008; 582(17):2655-62. DOI: 10.1016/j.febslet.2008.06.045. View

Wang G, Hamid T, Keith R, Zhou G, Partridge C, Xiang X . Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. Circulation. 2010; 121(17):1912-25. PMC: 2917269. DOI: 10.1161/CIRCULATIONAHA.109.905471. View

Weisberg E, Manley P, Breitenstein W, Bruggen J, Cowan-Jacob S, Ray A . Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005; 7(2):129-41. DOI: 10.1016/j.ccr.2005.01.007. View

Tibullo D, Barbagallo I, Giallongo C, La Cava P, Parrinello N, Vanella L . Nuclear translocation of heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells. Curr Pharm Des. 2012; 19(15):2765-70. DOI: 10.2174/1381612811319150012. View

10.

Wegiel B, Gallo D, Csizmadia E, Harris C, Belcher J, Vercellotti G . Carbon monoxide expedites metabolic exhaustion to inhibit tumor growth. Cancer Res. 2013; 73(23):7009-21. PMC: 3851591. DOI: 10.1158/0008-5472.CAN-13-1075. View

11.

Sass G, Leukel P, Schmitz V, Raskopf E, Ocker M, Neureiter D . Inhibition of heme oxygenase 1 expression by small interfering RNA decreases orthotopic tumor growth in livers of mice. Int J Cancer. 2008; 123(6):1269-77. DOI: 10.1002/ijc.23695. View

12.

Shah N, Tran C, Lee F, Chen P, Norris D, Sawyers C . Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004; 305(5682):399-401. DOI: 10.1126/science.1099480. View

13.

Baccarani M, Castagnetti F, Gugliotta G, Palandri F, Rosti G . Treatment recommendations for chronic myeloid leukemia. Mediterr J Hematol Infect Dis. 2014; 6(1):e2014005. PMC: 3894838. DOI: 10.4084/MJHID.2014.005. View

14.

Sacha T . Imatinib in chronic myeloid leukemia: an overview. Mediterr J Hematol Infect Dis. 2014; 6(1):e2014007. PMC: 3894842. DOI: 10.4084/MJHID.2014.007. View

15.

Liu M, Li D, Aneja R, Joshi H, Xie S, Zhang C . PO(2)-dependent differential regulation of multidrug resistance 1 gene expression by the c-Jun NH2-terminal kinase pathway. J Biol Chem. 2007; 282(24):17581-6. DOI: 10.1074/jbc.M702206200. View

16.

Snabaitis A, Cuello F, Avkiran M . Protein kinase B/Akt phosphorylates and inhibits the cardiac Na+/H+ exchanger NHE1. Circ Res. 2008; 103(8):881-90. DOI: 10.1161/CIRCRESAHA.108.175877. View

17.

Bloom D, Jaiswal A . Phosphorylation of Nrf2 at Ser40 by protein kinase C in response to antioxidants leads to the release of Nrf2 from INrf2, but is not required for Nrf2 stabilization/accumulation in the nucleus and transcriptional activation of antioxidant response.... J Biol Chem. 2003; 278(45):44675-82. DOI: 10.1074/jbc.M307633200. View

18.

Miyake M, Fujimoto K, Anai S, Ohnishi S, Kuwada M, Nakai Y . Heme oxygenase-1 promotes angiogenesis in urothelial carcinoma of the urinary bladder. Oncol Rep. 2011; 25(3):653-60. DOI: 10.3892/or.2010.1125. View

19.

Mayerhofer M, Gleixner K, Mayerhofer J, Hoermann G, Jaeger E, Aichberger K . Targeting of heat shock protein 32 (Hsp32)/heme oxygenase-1 (HO-1) in leukemic cells in chronic myeloid leukemia: a novel approach to overcome resistance against imatinib. Blood. 2007; 111(4):2200-10. DOI: 10.1182/blood-2006-11-055723. View

20.

Voss J, Posern G, Hannemann J, Wiedemann L, Turhan A, Poirel H . The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signalling pathways. Oncogene. 2000; 19(13):1684-90. DOI: 10.1038/sj.onc.1203467. View